A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs SYNT 001 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Acronyms WAIHA
- Sponsors Syntimmune
- 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.
- 01 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 01 Nov 2017 According to a Syntimmune media release, topline data from this trial is expected in the first half of 2018.